# GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

> **NCT05430373** · PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 31 (estimated)

## Conditions studied

- Solid Tumors, Adult

## Interventions

- **BIOLOGICAL:** GT101

## Key facts

- **NCT ID:** NCT05430373
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-23
- **Primary completion:** 2025-09-25
- **Final completion:** 2026-06-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430373, "GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05430373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*